TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01673945

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUS-guided fine needle aspiration
Description: Each patient will undergo examination with the CLA-EUS or the FV-EUS, which will be selected based on the randomization process. FV-EUS will be performed using the newly available FV -EUS scope (TGF-Y0001-UC) that is compatible with last generation Aloka alpha 10. First, search of the presumed lesion will be performed and once visualize, its characteristics (size, echogenicity, margins, etc) will be recorded on data collection sheet. Fine needle aspiration will be performed under EUS guidance using a 19- ,22- or a 25-gauge fine needle or procore needles depending on endoscopist's preference
Study: NCT01056484

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Relapse Prevention for Alcohol Dependence
Description: All subjects receive outpatient standard of care (SOC) therapy for alcohol dependence. Experimental subjects also receive the Mindfulness Meditation Relapse Prevention ('meditation') intervention. The intervention is an extension of existing meditation-based therapies for stress, relapse prevention in addictive disorders, and depression. It has been patterned after Mindfulness Based Relapse Prevention and tailored to the specific needs of alcoholics. Its curriculum includes both meditation and traditional cognitive therapy relapse prevention components. The intervention consists of an 8-week, manualized meditation course (2 hours/week group sessions) guided by trained instructors. In addition, experimental subjects are asked to meditate at-home (30 min/day, 6 days/week) during the study.

Intervention type: OTHER
Group type: OTHER
Intervention: Wait-list control
Description: 'Standard of care' (SOC) outpatient therapy for alcohol dependence is provided to all subjects through their outpatient treatment centers and as recommended by their regular providers. Subjects in the control group receive SOC only. Subjects in the experimental arm will receive the study meditation intervention in addition to SOC.
Study: NCT01626287

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Frozen perineal pad
Description: Frozen ice pads will be provided as per participants' request

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warm water soaked Black Tea Bags
Description: warm water soaked black tea bags will be provided to participants' as per their request
Study: NCT03956784

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: E-assessed clinical and biological follow up
Description: Clinical questionnaire: self-evaluation of pain (0 to 10), resumption of transit, bleeding, fever, pulse. In case of no filling, the patient is contacted.~An automatic alert system is defined and divide the patient according to three situations:~* Normal situation~* Situation requiring the nurse to call back the patient and contact the surgeon if the assessment requires medical advice~* Disturbing situation requiring contact of the first-line surgeon if a potentially serious event is suspected. Each speaker's place is described for each item in the detailed protocols~Biological questionnaire:~Biological monitoring (blood count, Ionogram, C-Reactive Protein, urea, creatinine) is performed on D1, D3 and D7.~All information is accessible in real time by the surgeon who receives notifications by email and on his smartphone in case of clinical or biological abnormality on patient monitoring.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual at home follow up
Description: An information sheet on the clinical parameters to be monitored will be given to patients and will include the following information:~1. Immediate complications and warning signs:~   * Tachycardia\> 120 bpm~  * Dyspnea~  * Rectorragies and / or melena~  * Vomiting with or without presence of blood~  * Major abdominal pain (visual analogue scale\> 6/10)~  * Fever\> 38~2. Management to deal with complications: call the service and / or the surgeon~3. Actions to be performed by the patient after the exit:passage of the nurse during 10 days for anticoagulant morning and evening (identical in both study groups)~Each patient will be given a prescription to perform a C-Reactive Protein assay on D1, D3 and D7, similarly.
Study: NCT00875524

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYD dengue vaccine serotypes (1, 2, 3, 4).
Description: 0.5 mL, Subcutaneous

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Meningococcal Polysaccharide A+C; NaCl; Typhoid Vi polysaccharide
Description: Each at 0.5 mL, Subcutaneous, respectively
Study: NCT01673945

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-guided fine needle aspiration
Description: Each patient will undergo examination with the CLA-EUS or the FV-EUS, which will be selected based on the randomization process. FV-EUS will be performed using the newly available FV -EUS scope (TGF-Y0001-UC) that is compatible with last generation Aloka alpha 10. First, search of the presumed lesion will be performed and once visualize, its characteristics (size, echogenicity, margins, etc) will be recorded on data collection sheet. Fine needle aspiration will be performed under EUS guidance using a 19- ,22- or a 25-gauge fine needle or procore needles depending on endoscopist's preference
Study: NCT03512925

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized debriefing session of coercive measures
Description: Debriefing session following the developed guidelines including setting and themes.
Study: NCT03838263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 2 nivolumab infusion (240 mg IV) 2 weeks apart (on day 1 and day 15) followed by standard chemoradiation.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Chemoradiation
Description: Standard of Care chemoradiation for 7 weeks (70 Gray delivered to the tumor by IMRT) with high-dose cisplatin (100mg/m2) at week 1, 4 and 7

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoradiation
Description: Standard of Care chemoradiation for 7 weeks (70 Gray delivered to the tumor by IMRT) with high-dose cisplatin (100mg/m2) at week 1, 4 and 7
Study: NCT00682461

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: Marketed nicotine replacement therapy formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Nicotine prototype
Study: NCT04116463

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chronic Disease Self-Management Program (CDSMP)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Financial Self-Management Program (FSMP)
Study: NCT02286154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: For New Cohort participants, PK/PD data will be used to predict the most effective maximum tolerated dose. Old Cohort participants will receive hydroxyurea escalated to MTD as per local clinical guidelines.
Study: NCT02642653

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lovastatin
Description: Once per day dosing
Study: NCT01006408

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low Level Laser
Description: Low Level Laser twice a week for 8 weeks

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Placebo followed by Low Level Laser
Description: Placebo twice a week for 4 weeks then crossover to Low Level Laser twice a week for 4 weeks
Study: NCT01879657

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTATATE injection and PET scan
Description: 68Ga-DOTATATE will be given in tracer doses and injected intravenously to image Neuroendocrine tumors by Positron Emission Tomography.
Study: NCT02451475

Intervention type: DRUG
Group type: OTHER
Intervention: Amitriptyline
Description: Amitriptyline 25 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine
Description: Venlafaxine 75 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine
Description: Paroxetine 25 mg/day
Study: NCT02677389

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive educational material regarding physical activity and standardized emails with wellness tips and information on stress management

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Receive educational material regarding physical activity and standardized emails with wellness tips and information on stress management

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Receive email and technical or how-to support from study coordinator

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitoring Device
Description: Wear a Fitbit web-integrated physical activity tracker

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03821779

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale of anxiety
Description: Subjects will be asked to rate their anxiety levels~* immediately before (5 minutes of silent waiting),~* during~* and after the 5-minute oral presentation (recovery)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale of anxiety
Description: Subjects will be asked to rate their anxiety levels~* immediately before (5 minutes of silent waiting),~* during~* and after the 5-minute oral presentation (recovery)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale of anxiety
Description: Subjects will be asked to rate their anxiety levels~* immediately before (5 minutes of silent waiting),~* during~* and after the 5-minute oral presentation (recovery)
Study: NCT04410536

Intervention type: DRUG
Group type: OTHER
Intervention: Symptomatic drugs
Description: indomethacin suppository 50-100 mg or an oral triptan, on maximum 3 days/10 days, only in case of very severe headache- and to use metoclopramide

Intervention type: DRUG
Group type: OTHER
Intervention: Bridge therapy
Description: prednisone 25 mg , 2 tablets after breakfast for 5 days, one tablet for 3 days, half tablet for 2 days ; bromazepam 1.5 mg, 1 tablet after breakfast, lunch and dinner for every day; pantoprazole 40 mg, 1 tablet after dinner every day

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness program
Description: home based withdrawal program
Study: NCT02642653

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once per day dosing
Study: NCT03584893

Intervention type: PROCEDURE
Intervention: Blood sampling for Cholestanol Analysis
Description: Cholestanol analysis will be performed to see the Rate of juvenile cataract patients whose cholestanol test result is above threshold (3.75 mg/mL) and suspected CTX cases
Study: NCT00549419

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringers lactate, hydroxyethyl starch; norepinephrine, dobutamine
Description: The Control group will be assessed using the standard care of traditional vital signs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goal-directed hemodynamic therapy
Description: Ringers lactate, hydroxyethyl starch; norepinephrine, dobutamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Ringers lactate, hydroxyethyl starch; norepinephrine, dobutamine
Study: NCT00513344

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk Chocolate
Description: 1 portion

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control (polyphenol-free) Chocolate
Description: one portion
Study: NCT03671044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanosomal Docetaxel Lipid Suspension (75 mg/m2)
Description: Each vial containing lyophilized Docetaxel lipid powder, equivalent to 20 mg or 80 mg of anhydrous Docetaxel.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanosomal Docetaxel Lipid Suspension (100 mg/m2)
Description: Each vial containing lyophilized Docetaxel lipid powder, equivalent to 20 mg or 80 mg of anhydrous Docetaxel.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxotere® (100 mg/m2)
Description: Docetaxel Injection Concentrate; 20 mg/0.5 mL
Study: NCT01548638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galantamine ER
Description: The study will be performed using the 8mg and 16mg doses of galantamine hydrobromide-ER, which is currently marketed for the treatment of Alzheimer's disease. The dosing regimen, which follows FDA-approved guidelines, will be an initial 4 weeks of drug run-up at the lowest 8mg daily dose, followed by an additional one week of drug run-up at the higher dose of 16mg daily.~Participants will continue to take the 16mg daily during the 7-day quit week, for a total of 6 weeks of treatment with galantamine-ER.
Study: NCT03030040

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The self-help book: Williams, M. & Penman, D. (2011). Mindfulness: A practical guide to finding peace in a frantic world. London: Piatkus.
Description: Participants will be provided with a copy of the self-help book, and asked to read it and follow the activities outlined in it, over eight weeks. They will receive weekly standardized emails, to provide information about mindfulness and encouragement to engage with the self-help book.
Study: NCT01814423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine-base 50 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine-base 70 mg
Study: NCT04653662

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Earol
Description: Treated with Earol on both ears and subsequent removal after 6 days of application
Study: NCT03015532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011
Description: HTX-011 (bupivacaine/meloxicam), via instillation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011
Description: HTX-011 (bupivacaine/meloxicam), via instillation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011
Description: HTX-011 (bupivacaine/meloxicam), via instillation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011
Description: HTX-011 (bupivacaine/meloxicam), via instillation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Description: Saline placebo via injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Description: Saline placebo via injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivicaine HCl
Description: Bupivacaine HCl without epinephrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivicaine HCl
Description: Bupivacaine HCl without epinephrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Ropivacaine, via injection
Study: NCT04037085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Subjects in the intervention arm will receive infusion dosing as noted in arm/group descriptions at the time of cord clamping. Duration of infusion will be 12 hours. Concentrations of ketamine and ketamine metabolites (nor-ketamine, NKET; and dehydro-nor-ketamine, DHNK) are measured in maternal plasma and urine as well as breastmilk. Maternal side effects, adverse events, and efficacy endpoints will be measured over the 12 hour infusion and over 15 hours after infusion discontinuation.
Study: NCT02609477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Istradefylline
Description: Istradefylline 40, 80, 160 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Istradefylline
Description: Istradefylline 40, 80, 160 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Istradefylline
Description: Istradefylline 40, 80, 160 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phentermine 45 mg
Description: Phentermine 45 or 90 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phentermine 45 mg
Description: Phentermine 45 or 90 mg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04238247

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tiny Cargo, Big Deal/Abróchame Bien, Cuídame Bien (TCBD/ABCB) Basic Intervention
Description: A bilingual emergency department (ED)-based precision prevention intervention grounded in Self-Determination Theory. The Basic TCBD/ABCB intervention integrates one personalized counseling session based on principles of motivational interviewing (MI) and eHealth components including a tailored mobile-friendly educational website and short message service (SMS) text message communications with the goal of improving child passenger safety.~Participants receive monthly text message requests to submit photographs depicting the child as they usually travel. Feedback is provided via text message to correct any observed errors or misuse. Tailored informational and motivational text messages are sent twice each month.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tiny Cargo, Big Deal/Abróchame Bien, Cuídame Bien (TCBD/ABCB) Basic Intervention
Description: A bilingual emergency department (ED)-based precision prevention intervention grounded in Self-Determination Theory. The Basic TCBD/ABCB intervention integrates one personalized counseling session based on principles of motivational interviewing (MI) and eHealth components including a tailored mobile-friendly educational website and short message service (SMS) text message communications with the goal of improving child passenger safety.~Participants receive monthly text message requests to submit photographs depicting the child as they usually travel. Feedback is provided via text message to correct any observed errors or misuse. Tailored informational and motivational text messages are sent twice each month.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tiny Cargo, Big Deal/Abróchame Bien, Cuídame Bien (TCBD/ABCB) Enhanced Intervention
Description: The Enhanced TBDC/ABCB Intervention includes a second motivational interviewing session. Basic Intervention text messages continue with an additional 1-2 tailored text messages per month.
Study: NCT01964196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1517
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1517
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1517
Description: Oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study: NCT03730363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentamidine
Description: Pentamidine will be administered as an IV infusion on treatment day 1-3 of a 21-day cycle 3 cycles using 2, 3, and 4 mg/kg dose escalation schedules. Non-investigational agents will be administered as follows: Ifosfamide 5000 mg/m2, Carboplatin 5 area under curve (AUC), and Etoposide 100 mg/mg2.
Study: NCT01462279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiamine
Description: 200mg of intravenous thiamine in 50ml of D5W will be infused over 30 minutes once
Study: NCT02915120

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Real Pulsed Radiofrequency
Description: Pulsed Radiofrequency uses radiofrequency current in short (20 ms), high-voltage bursts; the silent phase (480 ms) allows time for heat elimination, generally keeping the target tissue below 42° C. The Radiofrequency (RF) electrode will be inserted through the canula, and RF lesions will be generated by applying pulsed RF treatment to the inferomedial (IM), superomedial (SM), and superolateral (SL) GN branches for 8 minutes at 42°C.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Pulsed Radiofrequency
Description: Control patients will undergo the same procedure. The sensorial and motor stimulations will be applied too. The RF electrode will be then inserted through the cannula, and RF lesions will be simulated without applying pulsed RF treatment to the IM, SM and SL, GN branches for 8 minutes each GN branch and the temperature of the electrode tip was not raised.
Study: NCT04808700

Intervention type: OTHER
Group type: OTHER
Intervention: Follow-up of Episealer implant
Description: Follow-up and radiographic evaluation in patients who received an Episealer implant
Study: NCT03604302

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fMRI Paradigms
Description: T2\*-weighted images will be acquired with a single-shot gradient echo echo-planar imaging (EPI) sequence in the axial orientation (TR=2500ms, TE=30ms, FA=80°, slice thickness=4 mm, FOV= 240mm2, matrix=64×64) covering the whole brain.
Study: NCT04334941

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy
Study: NCT01430312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azelaic acid pre-foam formulation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle pre-foam formulation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Water

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium lauryl sulfate
Study: NCT04537897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 474121
Description: BI474121
Study: NCT02609477

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01697345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Study: NCT03520049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01892852

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture treatment will be performed by licensed doctors in Traditional Korean Medicine using 0.20 mm (diameter) X 0.40 mm (length) sized disposable acupuncture 3 times per week for 3 weeks. Acupuncture points are GV20, GB20 (bilateral), LI11 (bilateral), LI10 (bilateral), EX-UE9 (bilateral), ST36 (bilateral), ST40 (bilateral), and EX-LE10 (bilateral). Each session lasts 20-30 minutes.